A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours

被引：0
|
作者：
Alison M. Schram
Leena Gandhi
Monica M. Mita
Lars Damstrup
Frank Campana
Manuel Hidalgo
Enrique Grande
David M. Hyman
Rebecca S. Heist
机构：
[1] Memorial Sloan Kettering Cancer Center,
[2] New York University Perlmutter Cancer Center,undefined
[3] Cedars-Sinai Medical Center,undefined
[4] Merck Serono,undefined
[5] Sanofi-Aventis,undefined
[6] Beth Israel Deaconess Medical Center,undefined
[7] Hospital Universitario Ramon y Cajal,undefined
[8] Massachusetts General Hospital,undefined
来源：
British Journal of Cancer | 2018年 / 119卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1471 / 1476
页数：5
相关论文
共 50 条
  • [31] A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies
    Juric, Dejan
    de Bono, Johann S.
    LoRusso, Patricia M.
    Nemunaitis, John
    Heath, Elisabeth I.
    Kwak, Eunice L.
    Macarulla Mercade, Teresa
    Geuna, Elena
    de Miguel-Luken, Maria Jose
    Patel, Chirag
    Kuida, Keisuke
    Sankoh, Serap
    Westin, Eric H.
    Zohren, Fabian
    Shou, Yaping
    Tabernero, Josep
    CLINICAL CANCER RESEARCH, 2017, 23 (17) : 5015 - 5023
  • [32] Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors
    Geoffrey I. Shapiro
    Patricia LoRusso
    Eunice Kwak
    Susan Pandya
    Charles M. Rudin
    Carla Kurkjian
    James M. Cleary
    Mary Jo Pilat
    Suzanne Jones
    Alex de Crespigny
    Jill Fredrickson
    Luna Musib
    Yibing Yan
    Matthew Wongchenko
    Hsin-Ju Hsieh
    Mary R. Gates
    Iris T. Chan
    Johanna Bendell
    Investigational New Drugs, 2020, 38 : 419 - 432
  • [33] Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors
    Shapiro, Geoffrey, I
    LoRusso, Patricia
    Kwak, Eunice
    Pandya, Susan
    Rudin, Charles M.
    Kurkjian, Carla
    Cleary, James M.
    Pilat, Mary Jo
    Jones, Suzanne
    de Crespigny, Alex
    Fredrickson, Jill
    Musib, Luna
    Yan, Yibing
    Wongchenko, Matthew
    Hsieh, Hsin-Ju
    Gates, Mary R.
    Chan, Iris T.
    Bendell, Johanna
    INVESTIGATIONAL NEW DRUGS, 2020, 38 (02) : 419 - 432
  • [34] Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer
    Rodon, Jordi
    Perez-Fidalgo, Alejandro
    Krop, Ian E.
    Burris, Howard
    Guerrero-Zotano, Angel
    Britten, Carolyn D.
    Becerra, Carlos
    Schellens, Jan
    Richards, Donald A.
    Schuler, Martin
    Abu-Khalaf, Maysa
    Johnson, Faye M.
    Ranson, Malcolm
    Edenfield, Jeff
    Silva, Antonio P.
    Hackl, Wolfgang
    Quadt, Cornelia
    Demanse, David
    Duval, Vincent
    Baselga, Jose
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 82 (02) : 285 - 298
  • [35] A Dose-Escalation Study with a Special Drug Delivery System (SDS) of BEZ235, a Novel Dual PI3K/mTOR Inhibitor, in Patients with Metastatic/Advanced Solid Tumors
    Rodon, J.
    Infante, J.
    Burris, H.
    Tabernero, J.
    Ranson, M. R.
    Rouyrre, N.
    Duval, V.
    Silva, A.
    Hackl, W.
    Baselga, J.
    CANCER RESEARCH, 2010, 70
  • [36] Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer
    Jordi Rodon
    Alejandro Pérez-Fidalgo
    Ian E. Krop
    Howard Burris
    Angel Guerrero-Zotano
    Carolyn D. Britten
    Carlos Becerra
    Jan Schellens
    Donald A. Richards
    Martin Schuler
    Maysa Abu-Khalaf
    Faye M. Johnson
    Malcolm Ranson
    Jeff Edenfield
    Antonio P. Silva
    Wolfgang Hackl
    Cornelia Quadt
    David Demanse
    Vincent Duval
    Jose Baselga
    Cancer Chemotherapy and Pharmacology, 2018, 82 : 285 - 298
  • [37] Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors
    Mita, Monica
    Fu, Siqing
    Piha-Paul, Sarina Anne
    Janku, Filip
    Mita, Alain
    Natale, Ronald
    Guo, Wei
    Zhao, Charles
    Kurzrock, Razelle
    Naing, Aung
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (05) : 616 - 626
  • [38] Phase I trial of MEK 1/2 inhibitor pimasertib combined with mTOR inhibitor temsirolimus in patients with advanced solid tumors
    Monica Mita
    Siqing Fu
    Sarina Anne Piha-Paul
    Filip Janku
    Alain Mita
    Ronald Natale
    Wei Guo
    Charles Zhao
    Razelle Kurzrock
    Aung Naing
    Investigational New Drugs, 2017, 35 : 616 - 626
  • [39] A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies
    Wise-Draper, Trisha M.
    Moorthy, Ganesh
    Salkeni, Mohamad A.
    Karim, Nagla Abdel
    Thomas, Hala Elnakat
    Mercer, Carol A.
    Beg, M. Shalaan
    O'Gara, Sue
    Olowokure, Olugbenga
    Fathallah, Hassana
    Kozma, Sara C.
    Thomas, George
    Rixe, Olivier
    Desai, Pankaj
    Morris, John C.
    TARGETED ONCOLOGY, 2017, 12 (03) : 323 - 332
  • [40] A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies
    Trisha M. Wise-Draper
    Ganesh Moorthy
    Mohamad A. Salkeni
    Nagla Abdel Karim
    Hala Elnakat Thomas
    Carol A. Mercer
    M. Shalaan Beg
    Sue O’Gara
    Olugbenga Olowokure
    Hassana Fathallah
    Sara C. Kozma
    George Thomas
    Olivier Rixe
    Pankaj Desai
    John C. Morris
    Targeted Oncology, 2017, 12 : 323 - 332
12345